Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spurred By Demand For Global And Regional Trials In India, China And Japan, ICON Charts Asia Growth Strategy

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - Malcolm Burgess, Executive VP Asia Pacific with Ireland-headquartered ICON Plc - one of the fastest growing contract research organizations in Asia - expresses satisfaction that over the past seven years he could develop a close bonding with his 600 plus staffers based in the medium-sized cities of Chennai and Thiruvananthapuram at the southern tip of India

You may also be interested in...



ICON Goes Local As China CRO Market Heats Up

Acquisition of BeijingWits will boost ICON’s clinical trial capabilities in China and the Asia Pacific region.

Korea's Celltrion Deepens Cooperation With PPD For Entire Biosimilar Portfolio

SEOUL - South Korea's biosimilar front-runner Celltrion Inc. signed a memorandum of understanding with contract research organization Pharmaceutical Product Development Inc. to expand their ongoing cooperation in clinical trials to Celltrion's seven remaining biosimilars as well as its future biologic development projects

Korea's Celltrion Deepens Cooperation With PPD For Entire Biosimilar Portfolio

SEOUL - South Korea's biosimilar front-runner Celltrion Inc. signed a memorandum of understanding with contract research organization Pharmaceutical Product Development Inc. to expand their ongoing cooperation in clinical trials to Celltrion's seven remaining biosimilars as well as its future biologic development projects

Related Content

UsernamePublicRestriction

Register

SC010771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel